nach oben

Drugs & Aging

Erschienen in:

01.07.2007 | Leading Article

Neuroprotective Effects of Free Radical Scavengers in Stroke

verfasst von: Dr Chen X. Wang, Ashfaq Shuaib

Erschienen in: Drugs & Aging | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Acute ischaemic stroke is a leading cause of death in the majority of industrialised countries and also in many developing countries. Free radicals are generated in the brain during ischaemic injury and these radicals are involved in the secondary injury processes. Several free radical scavengers have been developed and some of them have progressed into clinical trials. One of them, edaravone, has been approved by the regulatory authority in Japan for the treatment of stroke patients. Another scavenger, disodium 4-[(tert-butylimino)methyl] benzene-1,3-disulfonate N-oxide (NXY-059; disufenton), has demonstrated efficacy in a phase III clinical trial (SAINT [Stroke Acute Ischaemic NXY-059 Treatment study]-I) involving a large number of stroke patients. Unfortunately, SAINT II did not show efficacy in the treatment of stroke patients. The purpose of this article is to review the current development of antioxidant strategies, update recent findings for NXY-059 in the treatment of stroke patients, and discuss the future development of neuroprotective agents. Although the development of neuroprotective strategies for the treatment of stroke is challenging, progress in molecular and cellular neuroscience will uncover new information about stroke mechanisms, which should result in the realisation of neuroprotective therapy for this disease.

Green AR, Shuaib A. Therapeutic strategies for the treatment of stroke. Drug Discov Today 2006 Aug; 11(15–16): 681–93PubMedCrossRef

He J, Klag MJ, Wu Z, et al. Stroke in the People’s Republic of China I: geographic variations in incidence and risk factors. Stroke 1995 Dec; 26(12): 2222–7PubMedCrossRef

Flamm ES, Demopoulos HB, Seligman ML, et al. Free radicals in cerebral ischemia. Stroke 1978 Sep–Oct; 9(5): 445–7PubMedCrossRef

Morimoto T, Globus MY, Busto R, et al. Simultaneous measurement of salicylate hydroxylation and glutamate release in the penumbral cortex following transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1996 Jan; 16(1): 92–9PubMedCrossRef

Watson BD, Busto R, Goldberg WJ, et al. Lipid peroxidation in vivo induced by reversible global ischemia in rat brain. J Neurochem 1984 Jan; 42(1): 268–74PubMedCrossRef

Nelson CW, Wei EP, Povlishock JT, et al. Oxygen radicals in cerebral ischemia. Am J Physiol 1992 Nov; 263 (5 Pt 2): H1356–62PubMed

Cao W, Carney JM, Duchon A, et al. Oxygen free radical involvement in ischemia and reperfusion injury to brain. Neurosci Lett 1988 May 26; 88(2): 233–8PubMedCrossRef

Kato N, Yanaka K, Nagase S, et al. The antioxidant EPC-K1 ameliorates brain injury by inhibiting lipid peroxidation in a rat model of transient focal cerebral ischaemia. Acta Neurochir (Wien) 2003 Jun; 145(6): 489–93

Lancelot E, Callebert J, Revaud ML, et al. Detection of hydroxyl radicals in rat striatum during transient focal cerebral ischemia: possible implication in tissue damage. Neurosci Lett 1995 Sep 8; 197(2): 85–8PubMedCrossRef

10.

Schmid-Elsaesser R, Zausinger S, Hungerhuber E, et al. Neuroprotective effects of combination therapy with tirilazad and magnesium in rats subjected to reversible focal cerebral ischemia. Neurosurgery 1999 Jan; 44(1): 163–71PubMedCrossRef

11.

Hallenbeck JM, Dutka AJ, Tanishima T, et al. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke 1986 Mar–Apr; 17(2): 246–53PubMedCrossRef

12.

Green AR, Ashwood T, Odergren T, et al. Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol Ther 2003 Dec; 100(3): 195–214PubMedCrossRef

13.

Yang Y, Li Q, Shuaib A. Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-ntert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia. Exp Neurol 2000 May; 163(1): 39–45PubMedCrossRef

14.

Yang G, Chan PH, Chen J, et al. Human copper-zinc Superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke 1994 Jan; 25(1): 165–70PubMedCrossRef

15.

Kinouchi H, Epstein CJ, Mizui T, et al. Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn Superoxide dismutase. Proc Natl Acad Sci U S A 1991 Dec 15; 88(24): 11158–62PubMedCrossRef

16.

Siesjo BK, Agardh CD, Bengtsson F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev 1989 Fall; 1(3): 165–211PubMed

17.

Rodrigo J, Fernandez AP, Serrano J, et al. The role of free radicals in cerebral hypoxia and ischemia. Free Radic Biol Med 2005 Jul 1; 39(1): 26–50PubMedCrossRef

18.

Alexandrova ML, Bochev PG. Oxidative stress during the chronic phase after stroke. Free Radic Biol Med 2005 Aug 1; 39(3): 297–316PubMedCrossRef

19.

Schaller B. Introduction to serial reviews on free radicals and stroke. Free Radic Biol Med 2005 Feb 15; 38(4): 409–10PubMedCrossRef

20.

Moro MA, Almeida A, Bolanos JP, et al. Mitochondrial respiratory chain and free radical generation in stroke. Free Radic Biol Med 2005 Nov 15; 39(10): 1291–304PubMedCrossRef

21.

Chan PH. Role of oxidants in ischemic brain damage. Stroke 1996 Jun; 27(6): 1124–9PubMedCrossRef

22.

Stadtman ER, Oliver CN. Metal-catalyzed oxidation of proteins: physiological consequences. J Biol Chem 1991 Feb 5; 266(4): 2005–8PubMed

23.

Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982 Nov; 47(5): 412–26PubMed

24.

Kehrer JP. Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol 1993; 23(1): 21–48PubMedCrossRef

25.

Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003 May; 4(5): 399–415PubMedCrossRef

26.

Hengartner MO. The biochemistry of apoptosis. Nature 2000 Oct 12; 407(6805): 770–6PubMedCrossRef

27.

Yuan J, Yankner BA. Apoptosis in the nervous system. Nature 2000 Oct 12; 407(6805): 802–9PubMedCrossRef

28.

Beckman JS. Interactions of oxidants, nitric oxide and antioxidant defences in cerebral ischemia and injury. In: Ginsberg M, Bogousslavsky J, editors. Maiden: Blackwell Science, 1998: 455–70

29.

Margaill I, Plotkine M, Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radic Biol Med 2005 Aug 15; 39(4): 429–43PubMedCrossRef

30.

Noguchi N, Yoshida Y, Kaneda H, et al. Action of ebselen as an antioxidant against lipid peroxidation. Biochem Pharmacol 1992 Jul 7; 44(1): 39–44PubMedCrossRef

31.

Dawson DA, Masayasu H, Graham DI, et al. The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci Lett 1995 Feb 6; 185(1): 65–9PubMedCrossRef

32.

Takasago T, Peters EE, Graham DI, et al. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br J Pharmacol 1997 Nov; 122(6): 1251–6PubMedCrossRef

33.

Imai H, Masayasu H, Dewar D, et al. Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke 2001 Sep; 32(9): 2149–54PubMedCrossRef

34.

Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator-induced hemorrhage after thromboembolic stroke. Stroke 2000 Dec; 31(12): 3034–40PubMedCrossRef

35.

Salom JB, Perez-Asensio FJ, Burguete MC, et al. Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia. Eur J Pharmacol 2004 Jul 8; 495(1): 55–62PubMedCrossRef

36.

Ogawa A, Yoshimoto T, Kikuchi H, et al. Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis 1999 Mar–Apr; 9(2): 112–8PubMedCrossRef

37.

Yamaguchi T, Sano K, Takakura K, et al. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 1998 Jan; 29(1): 12–7PubMedCrossRef

38.

Schmid-Elsaesser R, Zausinger S, Hungerhuber E, et al. Monotherapy with dextromethorphan or tirilazad — but not a combination of both — improves outcome after transient focal cerebral ischemia in rats. Exp Brain Res 1998 Sep; 122(1): 121–7PubMedCrossRef

39.

Bath PM, Iddenden R, Bath FJ, et al. Tirilazad for acute ischaemic stroke. Cochrane Database Syst Rev 2001; (4): CD002087

40.

van der Worp HB, Kappelle LJ, Algra A, et al. The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. Neurology 2002 Jan 8; 58(1): 133–5PubMedCrossRef

41.

Zhu C, Wang X, Huang Z, et al. Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ 2007; 14: 775–84PubMedCrossRef

42.

Noor JI, Ikeda T, Mishima K, et al. Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy. Stroke 2005; 36: 2468–74PubMedCrossRef

43.

Shichinohe H, Kuroda S, Yasuda H, et al. Neuroprotective effects of the free radical scavenger edaravone (MCI-186) in mice permanent focal brain ischemia. Brain Res 2004 Dec 17; 1029(2): 200–6PubMedCrossRef

44.

Zhang N, Komine-Kobayashi M, Tanaka R, et al. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005; 36: 2220–5PubMedCrossRef

45.

Amemiya S, Kamiya T, Nito C, et al. Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. Eur J Pharmacol 2005 Jun 1; 516(2): 125–30PubMedCrossRef

46.

Edaravone Acute Infarction Study Group. Randomized, placebo-controlled, double-blind study at multicenters: effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Cerebrovasc Dis 2003; 15(3): 222–9CrossRef

47.

Maples KR, Ma F, Zhang YK. Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059. Free Radic Res 2001 Apr; 34(4): 417–26PubMedCrossRef

48.

Green AR, Ashwood T. Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Curr Drug Targets CNS Neurol Disord 2005 Apr; 4(2): 109–18PubMedCrossRef

49.

Kuroda S, Tsuchidate R, Smith ML, et al. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999 Jul; 19(7): 778–87PubMedCrossRef

50.

Yoshimoto T, Kanakaraj P, Ying Ma J, et al. NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia. Brain Res 2002 Aug 30; 947(2): 191–8PubMedCrossRef

51.

Yoshimoto T, Kristian T, Hu B, et al. Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A. Brain Res 2002 Apr 5; 932(1–2): 99–109PubMedCrossRef

52.

Zhao Z, Cheng M, Maples KR, et al. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 2001 Aug 3; 909(1—2): 46–50PubMedCrossRef

53.

Marshall JW, Cummings RM, Bowes LJ, et al. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 2003 Sep; 34(9): 2228–33PubMedCrossRef

54.

Marshall JW, Duffin KJ, Green AR, et al. NXY-059, a free radical: trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001 Jan; 32(1): 190–8PubMedCrossRef

55.

Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006 Feb 9; 354(6): 588–600PubMedCrossRef

56.

Peeling J, Del Bigio MR, Corbett D, et al. Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology 2001 Mar; 40(3): 433–9PubMedCrossRef

57.

Hankey GJ. Neuroprotection for acute ischaemic stroke: hope reignited. Lancet Neurol 2006 Apr; 5(4): 287–8PubMedCrossRef

58.

Schaller B, Graf R, Jacobs AH. Ischaemic tolerance: a window to endogenous neuroprotection? Lancet 2003 Sep 27; 362(9389): 1007–8PubMedCrossRef

59.

Saver JL, Kidwell C, Eckstein M, et al. Physician-investigator phone elicitation of consent in the field: a novel method to obtain explicit informed consent for prehospital clinical research. Prehosp Emerg Care 2006 Apr–Jun; 10(2): 182–5PubMedCrossRef

60.

American Stroke Association. Major ongoing stroke trials. Stroke 2006 Feb; 37(2): e18–26

Titel: Neuroprotective Effects of Free Radical Scavengers in Stroke
verfasst von: Dr Chen X. Wang
Ashfaq Shuaib
Publikationsdatum: 01.07.2007
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 7/2007
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200724070-00002

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Sustained-Release Ophthalmic Drug Delivery Systems for Treatment of Macular Disorders

Glucosamine and Chondroitin Sulfate as Therapeutic Agents for Knee and Hip Osteoarthritis

Acute Exacerbations of Chronic Bronchitis in Elderly Patients

Clinical Perspectives on Bone Quality in Osteoporosis

Characterisation of Patients with Postmenopausal Osteoporosis in French Primary Healthcare